Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance

Critical Reviews in Oncology/Hematology

Volumn 79, Issue 2, 2011, Pages 112-126

  Kim, Young June ^a   Broxmeyer, Hal E ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cord blood transplantation; Dendritic cells; Mesenchymal stromal stem cells; Natural killer cells; Regulatory T cells; T lymphocytes; Transplantation tolerance

Indexed keywords

CALCINEURIN INHIBITOR; STEROID;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD34 SELECTION; CD4+ CD25+ T LYMPHOCYTE; CORD BLOOD STEM CELL TRANSPLANTATION; DENDRITIC CELL; DISEASE SEVERITY; FANCONI ANEMIA; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOCOMPETENT CELL; MESENCHYMAL STEM CELL; MONONUCLEAR CELL; NATURAL KILLER CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; STROMA CELL; TH1 CELL; TRANSPLANTATION TOLERANCE; UMBILICAL CORD BLOOD;

ADULT; ANIMALS; ANTIGENS, CD; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CORD BLOOD STEM CELL TRANSPLANTATION; DENDRITIC CELLS; FEMALE; FETAL BLOOD; FETUS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; KILLER CELLS, NATURAL; MESENCHYMAL STEM CELLS; MICE; MICE, SCID; PREGNANCY; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 79960155788     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.07.009     Document Type: Review

References (223)

1. Broxmeyer H.E., Srour E.F., Hangoc G., et al. High-efficiency recovery of functional hematopoietic progenitor and stem cells from human cord blood cryopreserved for 15 years. Proc Natl Acad Sci U S A 2003, 100:645-650.
2. Komanduri K.V., St.John L.S., De Lima M., et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 2007, 110:4543-4551.
3. Szabolcs P., Cairo M.S. Unrelated umbilical cord blood transplantation and immune reconstitution. Semin Hematol 2010, 47:22-36.
4. Szabolcs P., Niedzwiecki D. Immune reconstitution after unrelated cord blood transplantation. Cytotherapy 2007, 9:111-122.
5. Parody R., Martino R., Rovira M., et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant 2006, 12:734-748.
6. Szabolcs P., Niedzwiecki D. Immune reconstitution in children after unrelated cord blood transplantation. Biol Blood Marrow Transplant 2008, 14:66-72.
7. Macmillan M.L., Weisdorf D.J., Brunstein C.G., et al. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood 2009, 113:2410-2415.
8. Gluckman E., Devergie A., Bourdeau-Esperou H., et al. Transplantation of umbilical cord blood in Fanconi's anemia. Nouv Rev Fr Hematol 1990, 32:423-425.
9. Gluckman E., Broxmeyer H.E., Auerbach A.D., et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989, 321:1174-1178.
10. Broxmeyer H.E., Douglas G.W., Hangoc G., et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci U S A 1989, 86:3828-3832.
11. Broxmeyer H.E., Smith F. Cord blood hematopoietic cell transplantation. Thomas' hematopoietic cell transplantation 2009, p. 559-76. 4th edition. F.R. Appelbaum, S.J. Forman, R.S. Negrin (Eds.).
12. Matsuno N., Wake A., Uchida N., et al. Impact of HLA disparity in the graft-versus-host direction on engraftment in adult patients receiving reduced-intensity cord blood transplantation. Blood 2009, 114:1689-1695.
13. Barker J.N., Davies S.M., Defor T., et al. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 2001, 97:2957-2961.
14. Rocha V., Wagner J.E., Sobocinski K.A., et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. N Engl J Med 2000, 342:1846-1854.
15. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004, 351:2276-2285.
16. Leung A.Y.H., Kwong Y.-L. Haematopoietic stem cell transplantation: current concepts and novel therapeutic strategies. Br Med Bull 2009, ldp040.
17. Canto E., Rodriguez-Sanchez J.L., Vidal S. Distinctive response of naive lymphocytes from cord blood to primary activation via TCR. J Leukoc Biol 2003, 74:998-1007.
18. Chen L., Cohen A.C., Lewis D.B. Impaired allogeneic activation and T-helper 1 differentiation of human cord blood naive CD4 T cells. Biol Blood Marrow Transplant 2006, 12:160-171.
19. Risdon G., Gaddy J., Broxmeyer H.E. Allogeneic responses of human umbilical cord blood. Blood Cells 1994, 20:566-570.
20. Risdon G., Gaddy J., Stehman F.B., et al. Proliferative and cytotoxic responses of human cord blood T lymphocytes following allogeneic stimulation. Cell Immunol 1994, 154:14-24.
21. + regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 2003, 112:1688-1696.
22. Reen D.J. Activation and functional capacity of human neonatal CD4 T-cells. Vaccine 1998, 16:1401-1408.
23. Yi T., Chen Y., Wang L., et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 2009, 114:3101-3112.
24. Yi T., Zhao D., Lin C.L., et al. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood 2008, 112:2101-2110.
25. Fowler D., Kurasawa K., Smith R., et al. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 1994, 84:3540-3549.
26. Krenger W., Ferrara J.L. Graft-versus-host disease and the Th1/Th2 paradigm. Immunol Res 1996, 15:50-73.
27. Nitsche A., Zhang M., Clauss T., et al. Cytokine profiles of cord and adult blood leukocytes: differences in expression are due to differences in expression and activation of transcription factors. BMC Immunol 2007, 8:18.
28. Szabo S.J., Sullivan B.M., Peng S.L., et al. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 2003, 21:713-758.
29. + T lymphocytes during primary stimulation. Blood 2003, 102:4608-4617.
30. Yang Y.G., Dey B.R., Sergio J.J., et al. Donor-derived interferon γ is required for inhibition of acute graft-versus-host disease by interleukin 12. J Clin Invest 1998, 102:2126-2135.
31. Murphy W.J., Welniak L.A., Taub D.D., et al. Differential effects of the absence of interferon-γ and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest 1998, 102:1742-1748.
32. Burman A.C., Banovic T., Kuns R.D., et al. IFNγ differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood 2007, 110:1064-1072.
33. Keir M.E., Butte M.J., Freeman G.J., et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
34. Kappel L.W., Goldberg G.L., King C.G., et al. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood 2009, 113:945-952.
35. Carlson M.J., West M.L., Coghill J.M., et al. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 2009, 113:1365-1374.
36. + T cell-mediated graft-versus-host disease 1. Transplantation 1998, 66:1220-1229.
37. +T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997, 389:737-742.
38. Rainsford E., Reen D.J. Interleukin 10, produced in abundance by human newborn T cells, may be the regulator of increased tolerance associated with cord blood stem cell transplantation. Br J Haematol 2002, 116:702-709.
39. Chakraverty R., Sykes M. The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood 2007, 110:9-17.
40. Chunduri S., Mahmud D., Abbasian J., et al. Cord blood nucleated cells induce delayed T cell alloreactivity. Biol Blood Marrow Transplant 2008, 14:872-879.
41. - population. Blood 1999, 93:2302-2307.
42. - dendritic cell subsets in cord blood. Br J Haematol 2001, 113:925-931.
43. Kollmann T.R., Crabtree J., Rein-Weston A., et al. Neonatal innate TLR-mediated responses are distinct from those of adults. J Immunol 2009, 183:7150-7160.
44. Sandeep C., Dolores M., Javaneh A., et al. Cord blood nucleated cells induce delayed T cell alloreactivity. biology of blood and marrow transplantation. J Am Soc Blood Marrow Transplant 2008, 14:872-879.
45. Liu E., Tu W., Law H.K.W., et al. Decreased yield, phenotypic expression and function of immature monocyte-derived dendritic cells in cord blood. Br J Haematol 2001, 113:240-246.
46. Rescigno M., Martino M., Sutherland C.L., et al. Dendritic cell survival and maturation are regulated by different signaling pathways. J Exp Med 1998, 188:2175-2180.
47. Banchereau J., Briere F., Caux C., et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:767-811.
48. + memory T cells migrate in a CD62P-dependent fashion into reactive lymph nodes and license dendritic cells for T cell priming. J Exp Med 2008, 205:2561-2574.
49. Drohan L., Harding J.J., Holm B., et al. Selective developmental defects of cord blood antigen-presenting cell subsets. Human Immunol 2004, 65:1356-1369.
50. Goriely S., Vincart B., Stordeur P., et al. Deficient IL-12(p35) gene expression by dendritic cells derived from neonatal monocytes. J Immunol 2001, 166:2141-2146.
51. Langrish C.L., Buddle J.C., Thrasher A.J., et al. Neonatal dendritic cells are intrinsically biased against Th-1 immune responses. Clin Exp Immunol 2002, 128:118-123.
52. Naderi N., Pourfathollah A.A., Alimoghaddam K., et al. Cord blood dendritic cells prevent the differentiation of naive T-helper cells towards Th1 irrespective of their subtype. Clin Exp Med 2009, 9:29-36.
53. Arpinati M., Chirumbolo G., Urbini B., et al. Role of plasmacytoid dendritic cells in immunity and tolerance after allogeneic hematopoietic stem cell transplantation. Transplant Immunol 2003, 11:345-356.
54. Crespo I., Paiva A., Couceiro A., et al. Immunophenotypic and functional characterization of cord blood dendritic cells. Stem Cells Dev 2004, 13:63-70.
55. Mahnke K., Schmitt E., Bonifaz L., et al. Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol Cell Biol 2002, 80:477-483.
56. Steinbrink K., Mahnke K., Grabbe S., et al. Myeloid dendritic cell: from sentinel of immunity to key player of peripheral tolerance?. Human Immunol 2009, 70:289-293.
57. + dendritic cells reduces experimental acute GVHD in an IL-10-dependent manner. Blood 2010, 115:724-735.
58. Kubach J., Becker C., Schmitt E., et al. Dendritic cells: sentinels of immunity and tolerance. Int J Hematol 2005, 81:197-203.
59. Rutella S., Danese S., Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006, 108:1435-1440.
60. Chidgey A.P., Layton D., Trounson A., et al. Tolerance strategies for stem-cell-based therapies. Nature 2008, 453:330-337.
61. Roncarolo M.G., Levings M.K., Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J Exp Med 2001, 193:F5-F9.
62. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000, 192:1213-1222.
63. + regulatory T cells including suppressors of alloreactivity. Immunol Rev 2006, 212:314-329.
64. Dhodapkar M.V., Steinman R.M., Krasovsky J., et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001, 193:233-238.
65. Jiang X.-X., Zhang Y., Liu B., et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005, 105:4120-4126.
66. Saito S., Motoyoshi K., Ichijo M., et al. High serum human macrophage colony-stimulating factor level during pregnancy. Int J Hematol 1992, 55:219-225.
67. Mellor A.L., Munn D.H. Immunology at the maternal-fetal interface: lessons for T cell tolerance and suppression. Annu Rev Immunol 2000, 18:367-391.
68. absent dendritic cells with tolerogenic potential. J Immunol 2005, 174:4706-4717.
69. Tolar J., Hippen K.L., Blazar B.R. Immune regulatory cells in umbilical cord blood: T regulatory cells and mesenchymal stromal cells. Br J Haematol 2009, 147:200-206.
70. Sakaguchi S., Sakaguchi N., Asano M., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
71. + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004, 22:531-562.
72. Fontenot J.D., Rasmussen J.P., Williams L.M., et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005, 22:329-341.
73. + T cells with regulatory properties from human blood. J Exp Med 2001, 193:1303-1310.
74. + regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002, 3:135-142.
75. + immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002, 16:311-323.
76. + T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 2005, 105:2845-2851.
77. + T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 2004, 104:3804-3812.
78. + regulatory T cells protects from lethal acute GVHD. Blood 2005, 105:2220-2226.
79. Wei S., Kryczek I., Zou W. Regulatory T-cell compartmentalization and trafficking. Blood 2006, 108:426-431.
80. + regulatory T Cells. J Exp Med 2001, 194:847-854.
81. + regulatory T cell activity in both humans and mice. J Immunol 2004, 172:834-842.
82. + T cells is facilitated by CTLA-4 signaling. J Immunol 2006, 177:2331-2339.
83. + regulatory T cells and for expansion of these cells. J Immunol 2007, 178:2018-2027.
84. H17 and regulatory T cells. Nature 2006, 441:235-238.
85. H17 cells. Nature 2007, 448:484-487.
86. Gao W., Lu Y., Essawy B.E., et al. Contrasting Effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007, 7:1722-1732.
87. Sauer S., Bruno L., Hertweck A., et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A 2008, 105:7797-7802.
88. Raimondi G., Sumpter T.L., Matta B.M., et al. Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients. J Immunol 2010, 184:624-636.
89. Asano M., Toda M., Sakaguchi N., et al. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 1996, 184:387-396.
90. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998, 160:1212-1218.
91. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998, 188:287-296.
92. + immunoregulatory T cells is antigen nonspecific. J Immunol 2000, 164:183-190.
93. Waldmann T.A. The interleukin-2 receptor. J Biol Chem 1991, 266:2681-2684.
94. Zola H., Fusco M., Macardle P.J., et al. Expression of cytokine receptors by human cord blood lymphocytes: comparison with adult blood lymphocytes. Pediatr Res 1995, 38:397-403.
95. + T cells. Immunology 1991, 72:15-19.
96. high regulatory cells in human peripheral blood. J Immunol 2001, 167:1245-1253.
97. + T cells in thymus,cord and adult blood. Immunology 2002, 106:190-199.
98. + regulatory T cells. Nat Immunol 2003, 4:330-336.
99. + regulatory T cells at the single-cell level. Eur J Immunol 2005, 35:1681-1691.
100. Seddiki N., Santner-Nanan B., Martinson J., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006, 203:1693-1700.
101. high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 2006, 108:4260-4267.
102. + regulatory T cells that express either CD45RA or CD45RO. J Immunol 2010, 184:4317-4326.
103. +-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood 2005, 105:750-758.
104. + regulatory T cells. Blood 2006, 107:1018-1023.
105. + cells: a naturally occurring population of regulatory T cells. Blood 2001, 98:2736-2744.
106. + T cells stimulated with anti-CD3/anti-CD28 and exogenous interleukin (IL)-2 or IL-15. Pediatric Allergy and Immunology 2009, 20:624-632.
107. + T cells. Eur J Immunol 2003, 33:579-587.
108. + regulatory T (Treg) cells: a comparative study of naive and antigenic-specific cord blood Treg cells. Exp Hematol 2005, 33:1508-1520.
109. Schaub B., Liu J., Hoppler S., et al. Maternal farm exposure modulates neonatal immune mechanisms through regulatory T cells. J Allergy Clin Immunol 2009, 123:774-782. e5.
110. Wood K.J., Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003, 3:199-210.
111. + T cells that survive irradiation regulate chronic graft-versus-host disease. Blood 2004, 104:1565-1573.
112. + regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood 2008, 112:2129-2138.
113. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001, 182:18-32.
114. + T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. Blood 2005, 105:1828-1836.
115. + Immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med 2002, 196:401-406.
116. + immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002, 99:3493-3499.
117. Chen X., Vodanovic-Jankovic S., Johnson B., et al. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 2007, 110:3804-3813.
118. + Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 2009, 31:772-786.
119. + regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006, 108:390-399.
120. Hippen K.L., Harker-Murray P., Porter S.B., et al. Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood 2008, 112:2847-2857.
121. + T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 2004, 104:453-461.
122. + regulatory T cells from the same cord blood unit. Exp Hematol 2007, 35:1562-1566.
123. Bacchetta R., Sartirana C., Levings M.K., et al. Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. Eur J Immunol 2002, 32:2237-2245.
124. + T cells that require antigen-specific activation for suppression. J Immunol 2003, 171:6431-6441.
125. + T cells. Blood 2008, 111:453-462.
126. + regulatory T cells from cord blood hematopoietic progenitor cells. J Leukoc Biol 2009, 85:445-451.
127. Martin C.H., Woll P.S., Ni Z., et al. Differences in lymphocyte developmental potential between human embryonic stem cell and umbilical cord blood-derived hematopoietic progenitor cells. Blood 2008, 112:2730-2737.
128. Abdallah B.M., Kassem M. Human mesenchymal stem cells: from basic biology to clinical applications. Gene Ther 2007, 15:109-116.
129. Bianco P., Robey P.G., Simmons P.J. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2008, 2:313-319.
130. Kern S., Eichler H., Stoeve J., et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord Blood, or adipose tissue. Stem Cells 2006, 24:1294-1301.
131. Pittenger M.F., Mackay A.M., Beck S.C., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
132. Cetrulo C.L.J. Cord-blood mesenchymal stem cells and tissue engineering. Stem Cell Rev 2006, 2:163-168.
133. Caplan A. Why are MSCs therapeutic? New data: new insight. J Pathol 2009, 217:318-324.
134. Phinney D.G., Prockop D.J. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair. Stem Cells 2007, 25:2896-2902.
135. Schugar R.C., Chirieleison S.M., Wescoe K.E., et al. High harvest yield, high expansion, and phenotype stability of CD146 mesenchymal stromal cells from whole primitive human umbilical cord tissue. J Biomed Biotechnol 2009, 2009:789526.
136. Prockop D.J. Repair of tissues by adult stem/progenitor cells (MSCs): Controversies, myths, and changing paradigms. Mol Ther 2009, 17:939-946.
137. Wang M., Yang Y., Yang D., et al. The immunomodulatory activity of human umbilical cord blood-derived mesenchymal stem cells in vitro. Immunology 2009, 126:220-232.
138. Ren G., Zhang L., Zhao X., et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008, 2:141-150.
139. Glennie S., Soeiro I., Dyson P.J., et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005, 105:2821-2827.
140. Maitra B., Szekely E., Gjini K., et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 2004, 33:597-604.
141. Keating A. Mesenchymal stromal cells. Curr Opin Hematol 2006, 13:419-425.
142. Rasmusson I., Ringdén O., Sundberg B., et al. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005, 305:33-41.
143. Augello A., Tasso R., Negrini S.M., et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005, 35:1482-1490.
144. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
145. Bartholomew A., Sturgeon C., Siatskas M., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002, 30:42-48.
146. Sato K., Ozaki K., Oh I., et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007, 109:228-234.
147. Beyth S., Borovsky Z., Mevorach D., et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005, 105:2214-2219.
148. Tisato V., Naresh K., Girdlestone J., et al. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia 2007, 21:1992-1999.
149. Romieu-Mourez R., Francois M., Boivin M.-N., et al. Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-γ, TGF-β, and cell density. J Immunol 2007, 179:1549-1558.
150. Batten P., Sarathchandra P., Antoniw Jw, et al. Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. Tissue Eng 2006, 12:2263-2273.
151. Groh M.E., Maitra B., Szekely E., et al. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 2005, 33:928-934.
152. Meisel R., Zibert A., Laryea M., et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
153. 2-dependent mechanism. Clin Immunol 2010.
154. Djouad F., Fritz V., Apparailly F., et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 2005, 52:1595-1603.
155. Gonzalez M.A., Gonzalez-Rey E., Rico L., et al. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 2009, 60:1006-1019.
156. Erices A., Conget P., Minguell J.J. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000, 109:235-242.
157. Lee Ok, Kuo T.K., Chen W.-M., et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004, 103:1669-1675.
158. Goodwin H.S., Bicknese A.R., Chien S.N., et al. Multilineage differentiation activity by cells isolated from umbilical cord blood: expression of bone, fat, and neural markers. Biol Blood Marrow Transplant 2001, 7:581-588.
159. Bieback K., Kern S., Klüter H., et al. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord bood. Stem Cells 2004, 22:625-634.
160. Secco M., Zucconi E., Vieira N.M., et al. Multipotent stem cells from umbilical cord: cord is richer than blood!. Stem Cells 2008, 26:146-150.
161. Wexler S.A., Donaldson C., Denning-Kendall P., et al. Adult bone marrow is a rich source of human mesenchymal 'stem' cells but umbilical cord and mobilized adult blood are not. Br J Haematol 2003, 121:368-374.
162. Mareschi K., Biasin E., Piacibello W., et al. Isolation of human mesenchymal stem cells: bone marrow versus umbilical cord blood. Haematologica 2001, 86:1099-1100.
163. Romanov Y.A., Svintsitskaya V.A., Smirnov V.N. Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells 2003, 21:105-110.
164. Wang H.-S., Hung S.-C., Peng S.-T., et al. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells 2004, 22:1330-1337.
165. Lu L.L., Liu Y.J., Yang S.G., et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica 2006, 91:1017-1026.
166. Boissel L., Tuncer H.H., Betancur M., et al. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells. Biol Blood Marrow Transplant 2008, 14:1031-1038.
167. Secco M., Moreira Y.B., Zucconi E., et al. Gene expression profile of mesenchymal stem cells from paired umbilical cord units: cord is different from blood. Stem Cell Rev 2009, 5:387-401.
168. Crisan M., Yap S., Casteilla L., et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008, 3:301-313.
169. Can A., Karahuseyinoglu S. Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells. Stem Cells 2007, 25:2886-2895.
170. Weiss M.L., Medicetty S., Bledsoe A.R., et al. Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells 2006, 24:781-792.
171. Weiss M.L., Troyer D.L. Stem cells in the umbilical cord. Stem Cell Rev 2006, 2:155-162.
172. + perivascular cells and fibroblasts. Exp Hematol 2008, 36:642-654.
173. Meirelles L.D.S., Caplan A.I., Nardi N.B. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 2008, 26:2287-2299.
174. Sarugaser R., Lickorish D., Baksh D., et al. Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells 2005, 23:220-229.
175. Baksh D., Yao R., Tuan R.S. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells 2007, 25:1384-1392.
176. Panepucci R.A., Siufi J.L.C., Silva W.A., et al. Comparison of gene expression of umbilical cord vein and bone marrow-derived mesenchymal stem cells. Stem Cells 2004, 22:1263-1278.
177. Friedman R., Betancur M., Boissel L., et al. Umbilical cord mesenchymal stem cells: adjuvants for human cell transplantation. Biol Blood Marrow Transplant 2007, 13:1477-1486.
178. Park I.H., Arora N., Huo H., et al. Disease-specific induced pluripotent stem cells. Cell 2008, 134:877-886.
179. Broxmeyer H.E. Will iPS cells enhance therapeutic applicability of cord blood cells and banking?. Cell Stem Cell 2010, 6:21-24.
180. Feldmann R.E.J., Bieback K., Maurer M.H., et al. Stem cell proteomes: a profile of human mesenchymal stem cells derived from umbilical cord blood. Electrophoresis 2005, 26:2749-2758.
181. Liu C.-H., Hwang S.-M. Cytokine interactions in mesenchymal stem cells from cord blood. Cytokine 2005, 32:270-279.
182. Yoo K.H., Jang I.K., Lee M.W., et al. Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol 2009, 259:150-156.
183. Bieback K., Kluter H. Mesenchymal stromal cells from umbilical cord blood. Curr Stem Cell Res Ther 2007, 2:310-323.
184. Bieback K., Kern S., Kocaomer A., et al. Comparing mesenchymal stromal cells from different human tissues: bone marrow, adipose tissue and umbilical cord blood. Biomed Mater Eng 2008, 18:S71-S76.
185. Rebelatto C.K., Aguiar A.M., Moretao M.P., et al. Dissimilar differentiation of mesenchymal stem cells from bone marrow, umbilical cord blood, and adipose tissue. Exp Biol Med 2008, 233:901-913.
186. Kakinuma S., Tanaka Y., Chinzei R., et al. Human umbilical cord blood as a source of transplantable hepatic progenitor cells. Stem Cells 2003, 21:217-227.
187. Kögler G., Sensken S., Airey Ja, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 2004, 200:123-135.
188. Kogler G., Sensken S., Wernet P. Comparative generation and characterization of pluripotent unrestricted somatic stem cells with mesenchymal stem cells from human cord blood. Exp Hematol 2006, 34:1589-1595.
189. Mcguckin C.P., Forraz N., Baradez M.-O., et al. Production of stem cells with embryonic characteristics from human umbilical cord blood. Cell Proliferation 2005, 38:245-255.
190. + very small embryonic-like cells purified from human cord blood-preliminary report. Leukemia 2006, 21:297-303.
191. Mueller S.M., Glowacki J. Age-related decline in the osteogenic potential of human bone marrow cells cultured in three-dimensional collagen sponges. J Cell Biochem 2001, 82:583-590.
192. Stenderup K., Justesen J., Clausen C., et al. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 2003, 33:919-926.
193. Rao M.S., Mattson M.P. Stem cells and aging: expanding the possibilities. Mech Ageing Dev 2001, 122:713-734.
194. Zappia E., Casazza S., Pedemonte E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106:1755-1761.
195. Lazarus H.M., Koc O.N., Devine S.M., et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005, 11:389-398.
196. Ringden O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
197. Sandhu J.S., Gorczynski R., Shpitz B., et al. A human model of xenogeneic graft-versus-host disease in SCID mice engrafted with human peripheral blood lymphocytes. Transplantation 1995, 60:179-184.
198. Sudres M., Norol F., Trenado A., et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 2006, 176:7761-7767.
199. Nauta A.J., Westerhuis G., Kruisselbrink Ab, et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006, 108:2114-2120.
200. Eliopoulos N., Stagg J., Lejeune L., et al. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 2005, 106:4057-4065.
201. Chung N.G., Jeong D.C., Park S.J., et al. Cotransplantation of marrow stromal cells may prevent lethal graft-versus-host disease in major histocompatibility complex mismatched murine hematopoietic stem cell transplantation. Int J Hematol 2004, 80:370-376.
202. Von Bonin M., Stolzel F., Goedecke A., et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2008, 43:245-251.
203. Zhou H., Guo M., Bian C., et al. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol Blood Marrow Transplant 2010, 16:403-412.
204. Gonzalo-Daganzo R., Regidor C., Martin-Donaire T., et al. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults. Cytotherapy 2009, 11:278-288.
205. Le Blanc K., Ringdén O. Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Curr Opin Immunol 2006, 18:586-591.
206. Olson J.A., Leveson-Gower D.B., Gill S., et al. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood 2010.
207. Xu W., Fazekas G., Hara H., et al. Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis. J Neuroimmunol 2005, 163:24-30.
208. Rabinovich B.A., Li J., Shannon J., et al. Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells. J Immunol 2003, 170:3572-3576.
209. - cells with low lytic activity are possible precursors of mature natural killer cells. Cell Immunol 1997, 180:132-142.
210. Fan Y.Y., Yang B.Y., Wu C.Y. Phenotypic and functional heterogeneity of natural killer cells from umbilical cord blood mononuclear cells. Immunol Invest 2008, 37:79-96.
211. Dalle J.-H., Menezes J., Wagner E., et al. Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections. Pediatric Res 2005, 57:649-655.
212. Wang Y., Xu H., Zheng X., et al. High expression of NKG2A/CD94 and low expression of granzyme B are associated with reduced cord blood NK cell activity. Cell Mol Immunol 2007, 4:377-382.
213. - NK cells in the peripheral blood of cord blood transplant recipients: a unique subset of NK cells possibly associated with graft-versus-leukemia effect. Eur J Haematol 2008, 81:18-25.
214. + natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A 2005, 102:2886-2891.
215. - NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNα and ribavirin. Clin Immunol 2008, 128:46-56.
216. High T-cells control potentially viremia in blood donors with HCV. J Med Virol 2009, 81:49-59.
217. Barker J.N., Weisdorf D.J., Defor T.E., et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005, 105:1343-1347.
218. Majhail N.S., Brunstein C.G., Wagner J.E. Double umbilical cord blood transplantation. Curr Opin Immunol 2006, 18:571-575.
219. Brunstein C.G., Barker J.N., Weisdorf D.J., et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007, 110:3064-3070.
220. Ballen K.K., Spitzer T.R., Yeap B.Y., et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007, 13:82-89.
221. Christopherson K.W., Hangoc G., Mantel C.R., et al. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004, 305:1000-1003.
222. + cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. Stem Cells Dev 2007, 16:347-354.
223. Campbell T.B., Broxmeyer H.E. CD26 inhibition and hematopoiesis: a novel approach to enhance transplantation. Front Biosci 2008, 13:1795-1805.